Hydrochlorothiazide efficacy and polymorphisms in ACE, ADD1 and GNB3 in healthy, male volunteers

European Journal of Clinical Pharmacology

Volumn 62, Issue 3, 2006, Pages 195-201

  Vormfelde, Stefan Viktor ^a   Sehrt, Daniel ^a   Bolte, Daniela ^a   Pahl, Susanne ^a   Tzvetkov, Mladen ^a   Brockmöller, Jürgen ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

ACE I D; ADD1; Diuretics; Genetic polymorphisms; GNB3; Hydrochlorothiazide

Indexed keywords

ADDUCIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIPORTER; CALCIUM ION; CHLORIDE ION; COTRANSPORTER; DIPEPTIDYL CARBOXYPEPTIDASE; GENOMIC DNA; GLYCINE; GUANINE NUCLEOTIDE BINDING PROTEIN BETA SUBUNIT; HYDROCHLOROTHIAZIDE; PLACEBO; POTASSIUM ION; SODIUM ION; THIAZIDE DIURETIC AGENT; TRYPTOPHAN;

ADULT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CALCIUM EXCRETION; CHLORIDE TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIURETIC ACTIVITY; DRUG EFFICACY; GENE INSERTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART RATE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOKALEMIA; MALE; MEAN ARTERIAL PRESSURE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POTASSIUM EXCRETION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SODIUM EXCRETION; URINARY EXCRETION; URINE VOLUME; VOLUNTEER;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CALCIUM; CALMODULIN-BINDING PROTEINS; CHLORIDES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HEART RATE; HETEROTRIMERIC GTP-BINDING PROTEINS; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; POTASSIUM; SINGLE-BLIND METHOD; SODIUM;

EID: 33644824403     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0081-z     Document Type: Article

References (31)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997
2. Vormfelde SV, Burckhardt G, Zirk A, Wojnowski L, Brockmoller J (2003) Pharmacogenomics of diuretic drugs: data on rare monogenic disorders and on polymorphisms and requirements for further research. Pharmacogenomics 4:701-734
3. Schelleman H, Stricker BH, De Boer A, Kroon AA, Verschuren MW, Van Duijn CM, Psaty BM, Klungel OH (2004) Drug-gene interactions between genetic polymorphisms and antihypertensive therapy. Drugs 64:1801-1816
4. Turner ST, Schwartz GL (2005) Gene markers and antihypertensive therapy. Curr Hypertens Rep 7:21-30
5. Bennett WM, McDonald WJ, Kuehnel E, Hartnett MN, Porter GA (1977) Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther 22:499-504
6. Rejnmark L, Vestergaard P, Pedersen AR, Heickendorff L, Andreasen F, Mosekilde L (2003) Dose-effect relations of loop-and thiazide-diuretics on calcium homeostasis: a randomized, double-blinded Latin-square multiple cross-over study in post-menopausal osteopenic women. Eur J Clin Invest 33:41-50
7. Rejnmark L, Mosekilde L, Andreasen F (1998) Diuretics and osteoporosis (in Danish). Nord Med 113:53-59
8. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE (2000) Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 133:516-526
9. Beermann B, Groschinsky-Grind M (1980) Clinical pharmacokinetics of diuretics. Clin Pharmacokinet 5:221-245
10. Beermann B, Groschinsky-Grind M (1977) Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 12:297-303
11. Cambien F, Alhenc-Gelas F, Herbeth B, Andre JL, Rakotovao R, Gonzales MF, Allegrini J, Bloch C (1988) Familial resemblance of plasma angiotensin- converting enzyme level: the Nancy Study. Am J Hum Genet 43:774-780
12. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346
13. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH (2005) Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111:3374-3383
14. Sciarrone MT, Stella P, Barlassina C, Manunta P, Lanzani C, Bianchi G, Cusi D (2003) ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy. Hypertension 41:398-403
15. Glorioso N, Filigheddu F, Cusi D, Troffa C, Conti M, Natalizio M, Argiolas G, Barlassina C, Bianchi G (2002) alpha-Adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives. Hypertension 39:357-362
16. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G (1997) Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 349:1353-1357
17. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E (2003) Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 16:834-839
18. Siffert W (2005) G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 56:17-28
19. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E (2001) C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 37:739-743
20. Feng Y, Niu T, Xu X, Chen C, Li Q, Qian R, Wang G, Xu X (2002) Insertion/deletion polymorphism of the ACE gene is associated with type 2 diabetes. Diabetes 51:1986-1988
21. Haszon I, Friedman AL, Papp F, Bereczki C, Baji S, Bodrogi T, Karoly E, Endreffy E, Turi S (2002) ACE gene polymorphism and renal scarring in primary vesicoureteric reflux. Pediatr Nephrol 17:1027-1031
22. Isaac G, Holland OB (1992) Drug-induced hypokalaemia. A cause for concern. Drugs Aging 2:35-41
23. Gennari FJ (1998) Hypokalemia. N Engl J Med 339:451-458
24. Velazquez H (1987) Thiazide diuretics. Ren Physiol 10:184-197
25. Cruz DN (2001) The renal tubular Na-Cl co-transporter (NCCT): a potential genetic link between blood pressure and bone density? Nephrol Dial Transplant 16:691-694
26. Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B (2004) Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine 71:51-55
27. Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, Pols HA, Stricker BH (2003) Thiazide diuretics and the risk for hip fracture. Ann Intern Med 139:476-482
28. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292:1326-1332
29. Schunkert H, Hense HW, Doring A, Riegger GA, Siffert W (1998) Association between a polymorphism in the G protein beta3 subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 32:510-513
30. Lee SY, Maniak PJ, Rhodes R, Ingbar DH, O'Grady SM (2003) Basolateral Cl-transport is stimulated by terbutaline in adult rat alveolar epithelial cells. J Membr Biol 191:133-139
31. Velazquez H, Silva T (2003) Cloning and localization of KCC4 in rabbit kidney: expression in distal convoluted tubule. Am J Physiol Renal Physiol 285:F49-F58